Lexicon Pharmaceuticals

38 articles about Lexicon Pharmaceuticals

• Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

  11/30/2023

  Lexicon Pharmaceuticals, Inc. today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

• Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

  11/22/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023.

• INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

  11/12/2023

  Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® use in heart failure and major adverse cardiovascular events related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events.

• Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

  11/10/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023.

• Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/8/2023

  Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended September 30th, 2023 and provided an update on key corporate milestones.

• Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023

  11/3/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open.

• Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

  11/2/2023

  Lexicon Pharmaceuticals, Inc. announced that five data presentations related to INPEFA® will be delivered during the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.

• INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

  11/1/2023

  Lexicon Pharmaceuticals, Inc. announced that Express Scripts, the pharmacy benefits management business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients.

• Lexicon Strengthens Management Team With Two New Executives

  10/31/2023

  Lexicon Pharmaceuticals, Inc. announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

• New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

  10/30/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to sotagliflozin, as well as data from a Lexicon-supported scientific study of patients hospitalized with heart failure who also had chronic kidney disease (CKD), will be presented during the American Society of Nephrology (ASN) Kidney Week Annual Meeting, November 2-5, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.

• Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

  10/17/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023.

• Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

  10/11/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting on October 16-19, 2023, in Orlando, Florida.

• Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

  10/9/2023

  Lexicon Pharmaceuticals, Inc. announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.

• INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients

  10/9/2023

  Lexicon Pharmaceuticals, Inc. announced that Express Scripts, the pharmacy benefits management business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023.

• Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

  9/28/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of clinical trial data for INPEFA® (sotagliflozin) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, October 6-9, 2023 in Cleveland, Ohio.

• Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

  9/26/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced several upcoming Lexicon-supported data presentations related to heart failure (HF), type 1 diabetes (T1D), and diabetic peripheral neuropathic pain (DPNP). The oral presentations will be made at the 59th Annual Meeting of EASD, October 2-6, 2023, in Hamburg, Germany and online.

• Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference

  9/7/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Conference, taking place September 11-13, 2023.

• Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

  9/7/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP).

• Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

  8/21/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online.

• Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

  8/8/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of data from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin has been published by the Journal of the American College of Cardiology (JACC): Heart Failure.